Background. Triple-negative breast cancer (TNBC) subtype and young patient age are both associated with an increased risk of local recurrence (LR) and distant recurrence (DR). In young women with TNBC, it is unclear whether subtype or patient age is driving prognosis. Methods. Patients treated for primary TNBC from 1998 to 2011 were identified from the breast surgery database. Clinicopathologic characteristics, treatment, and outcomes were compared between patients\40 and C40 years of age at diagnosis. Multivariate models were used to identify factors independently associated with LR and DR. Results. Among 1930 patients with TNBC, 289 (15 %) were \40 and 1641 (85 %) were C40 years of age at diagnosis. Younger patients were more likely to present with higher stage disease and more likely to receive mastectomy (p \ 0.01), axillary node dissection (p \ 0.01), and chemotherapy (p \ 0.01). At a median follow-up of 74 (0-201.1) months, there was no difference in LR or disease-free survival (DFS) by age group [5-year LR = 3.9 % (95 % confidence interval (CI) 1.5-6.2) vs. 4.5 % (95 % CI 3.5-5.6) and 5-year DFS = 75.3 % (95 % CI 70.2-80.7) vs. 77.7 % (95 % CI 75.6-79.8), p = 0.94] in patients aged \40 and C40 years, respectively. On multivariate analysis, larger tumor size, lymphovascular invasion, and nodal positivity were associated with increased risk of DR. Age and type of surgery were not significantly associated with either outcome. Conclusions. Young age at diagnosis is not an independent risk factor for LR or DR in patients with TNBC.
The triple-negative breast cancer (TNBC) subtype and young patient age have both been shown to impact breast cancer-specific outcomes. 1 Young breast cancer patients experience higher rates of local and distant recurrence (DR) compared to their older counterparts, yet they also frequently present with TNBC, a particularly aggressive breast cancer subtype associated with inferior outcomes. [2] [3] [4] Given the overlapping risk factors of young age and triplenegative subtype in young women with TNBC, it is unclear whether patient age or subtype is driving prognosis. We thus examined outcomes in a large population of patients with TNBC according to age.
METHODS

Patient Selection
All female patients treated for primary TNBC between January 1998 and December 2011 in the Department of Surgery at Memorial Sloan Kettering Cancer Center (MSKCC) were retrospectively identified by analysis of a prospectively maintained service database. Exclusion criteria were incomplete information about receptor status and stage IV disease at diagnosis. Treatment and outcome variables were abstracted from medical records. Triplenegative subtype was defined by the absence of estrogen receptor (ER) and progesterone receptor (PR) expression by immunohistochemistry, and the lack of HER-2 overexpression by immunohistochemistry, plus or minus a ratio of \2.0 by fluorescence in situ hybridization. The study was approved by the MSKCC institutional review board.
End Points and Statistical Analyses
Local recurrence (LR) was defined as ipsilateral breast or chest wall recurrence; regional recurrence (RR) as ipsilateral axillary, internal mammary or supraclavicular lymph node recurrence; and DRs were captured as single DR [visceral, lymph node (mediastinal, thoracic, cervical), brain, and bone] or multiple site recurrence. Charts were reviewed for date and disease status at last follow-up (no evidence of disease, alive with disease, died of disease, died of other cause, or died of unknown cause). Diseasefree survival (DFS) was defined as the time from date of diagnosis to diagnosis of LR, RR, or DR or death and censored at date of last follow-up.
Univariate comparisons were made between patients \40 and C40 years of age at diagnosis using v 2 tests, Fisher's exact tests and Wilcoxon rank-sum tests. LR, RR and DR were treated as competing events and when more than one type of recurrence occurred on the same day, the event was counted as the most serious type of recurrence. Death without recurrence was a competing event and follow-up was censored at the time of last follow-up for patients who were alive and recurrence free. Cumulative incidence of LR and DR were estimated using competing risks methodology and compared using Gray's test. Multivariate Fine and Gray regression was used to examine whether age was independently associated with LR and RR. Both models were adjusted for tumor size, grade (histologic and nuclear), type of surgery, lymphovascular invasion, chemotherapy, radiation, and nodal status. DFS was compared between groups with a log-tank test. Statistical analysis was performed by SAS 9.2 (SAS Institute, Cary, NC, USA) and R (R Foundation, Vienna, Austria) with the survival and cuminc packages, and p values of \0.05 were considered statistically significant.
RESULTS
We identified a total of 1971 patients treated for primary TNBC. Ten patients presented with stage IV disease and 31 had incomplete receptor status information and were excluded, leaving a total of 1930 patients who met the study criteria. Clinical, pathologic, and treatment variables are shown in Table 2 ). Rates of LR also did not significantly differ by age within each surgical procedure (Table 3) . 5-year LR rates among patients having breast-conserving therapy (BCT) were 2.3 % (95 % CI 2.3 0-4.5) for patients \40 years versus 4.5 % (95 % CI 2.9-6.2) for patients C40 years, and for those having mastectomy, 6.4 % (95 % CI 1.3-11.4) versus 4.5 % (95 % CI 3.1-5.9), respectively.
In contrast, the 5-year cumulative incidence of DR was significantly higher for younger patients compared to older patients (5-year DR 17. Table 2) .
On multivariate analysis, when adjusting for tumor characteristics and treatment, there was no correlation between the assessed parameters and an increased risk of LR whereas larger tumor size, lymphovascular invasion, and nodal positivity were associated with increased risk of DR (Table 4 ). Age and type of surgery were not significantly associated with either outcome.
DISCUSSION
A diagnosis of TNBC is associated with an increased risk of locoregional recurrence, an early peak of any recurrence in the first 2-3 years after diagnosis, and inferior clinical outcomes compared to other breast cancer subtypes. [5] [6] [7] Young age at diagnosis is also associated with an unfavorable prognosis. 8 Data assessing differences in age-dependent prognosis in TNBC patients are limited and have yielded conflicting results. 9, 10 In our large cohort of patients with TNBC treated at a single institution, age was not independently associated with LR, DR, DFS, or breast cancer-specific survival (BCSS). reported lower RFS and OS in patients \40 years of age for both time cohorts in luminal breast cancers. 13 The same association was present in HER-2-positive cancers, but only during the first time cohort in the absence of directed HER-2 therapy. In the TNBC subgroup, neither RFS nor OS were associated with age at diagnosis in either time cohort.
In contrast, when examining the effect of age on prognosis in 1732 patients with primary TNBC treated between 1982 and 2008 at a single institution, Liedtke et al. reported lower DFS, distant DFS, and OS rates in patients\40 years of age compared to older patients. 10 However, because the Liedtke study included patients diagnosed from 1982 onward and only 119 (33 %) of 366 patients \40 years of age received today's standard anthracycline and taxane based chemotherapy, these results have to be interpreted cautiously. BCT breast-conserving therapy, CI confidence interval, LN lymph node, LVI lymphovascular invasion, PMRT postmastectomy radiotherapy, RNRT regional nodal radiotherapy, WBRT whole-breast radiotherapy Similar to our results, Liedtke et al. found that younger patients with TNBC were more likely to present with high grade tumors of higher disease stage and with positive lymph nodes. 10 Unlike age at diagnosis, these clinicopathologic factors were associated with a higher incidence of LR and DR on multivariate analyses in our study. Similar to Liedtke et al., we found a higher 5-year cumulative incidence of distant metastases in patients \40 years of age, but this difference was no longer significant on multivariate analysis and therefore may be explained by the more advanced clinical stage at first diagnosis in the younger cohort.
Multiple studies have shown an increased risk of LR in TNBC compared to other breast cancer subtypes. 15 17 Among 7174 women treated with BCT, LR rates were 5 % for luminal, 13.5 % for triple-negative and 15.7 % for HER-2/neu-positive patients. More recent studies have reported significant reductions in LR for luminal and HER-2/ neu positive breast cancer subtypes as a result of improvements in endocrine and anti-HER-2 therapy. [18] [19] [20] However, LR rates for triple-negative tumors remain higher.
In our cohort, 5-year LR rates were much lower than reported by others, 3.9 % (95 % CI 1.5-6.2) in patients \40 years and 4.5 % (95 % CI 3.5-5.6) in patients C40 years of age. Improved outcomes in our study may reflect differences in systemic treatment. The meta-analysis conducted by Lowery et al. included 15 studies with patients treated between 1980 and 2008 and did not include detailed information about the receipt of chemotherapy or chemotherapeutic regimens. 17 Hence, the LR rate of 13.5 % for TNBC patients in the meta-analysis cannot be directly compared to a contemporarily treated TNBC population like ours in which 84 % of patients received chemotherapy.
Given the inferior outcomes of patients with TNBC, some have questioned whether or not more extensive surgery can overcome the aggressive biology of TNBC. Several studies have explored this question by comparing mastectomy and BCT outcomes in terms of LR and DR, DFS, and BCCS in TNBC patients; and all report no difference in outcomes by surgical procedure. [21] [22] [23] It has also been demonstrated that in the setting of BCT, margin width has no impact on LR. 24 Although our data demonstrate that rates of LR in TNBC have likely decreased with advances in systemic therapy, rates of LR in TNBC are still higher than in non-TNBC subtypes, and concern has been raised for young patients treated with BCT. We examined rates of LR by age in patients with TNBC according to type of surgery and found no differences in LR rates in patients treated with BCT \40 years versus C40 years of age.
Additionally on multivariate analysis type of surgery was not associated with development of LR or DR. Our findings now add to the accumulating evidence demonstrating that young patients with TNBC treated with BCT have similar outcomes to those treated with mastectomy and as such, young age should not be a contraindication for BCT. [24] [25] [26] [27] In contrast to rates of LR, we did observe higher rates of DR in the younger group, yet this observation did not translate into inferior DFS. This finding seems contradictory at first, but can be explained by the fact that although DR was more common in younger patients, death without DR was more common in older patients. Thus, when viewed in terms of competing events, there are no significant differences in DFS between the two age groups.
To our knowledge, this is the largest single institution study assessing the impact of age at diagnosis on clinical outcomes in patients with TNBC. However, our study is limited by the retrospective nature and incomplete information on BRCA mutation status in the majority of patients. There is a strong association between BRCA mutation status and breast cancer subtype, with 70-90 % of BRCA1 mutation-associated breast cancers being TNBC and 8-30 % of TNBC harboring a BRCA1 mutation. 28, 29 Further, BRCA1 mutations have been reported in up to 44 % of patients \40 years of age and BRCA1-associated cancers treated with BCT have been associated with a higher incidence of LR compared to non-BRCA-associated tumors. 30, 31 These considerations should be taken into account when discussing surgical treatment options in BRCA mutation carriers; however, in the absence of BRCA mutation, young age and TNBC subtype should not be considered as a contraindication to BCT.
CONCLUSIONS
Young patients with TNBC are more likely to present with higher stage disease compared to their older counterparts. However, after adjusting for stage, grade, and treatment, young age is not associated with an increased risk of LR or DR, or with inferior survival outcomes among women with TNBC.
